Tonix Pharmaceuticals (TNXP) said Monday that the US Food and Drug Administration will not require an advisory committee meeting regarding its new drug application for TNX-102 SL, a product candidate to treat fibromyalgia.
The biopharmaceutical company said the drug candidate is on track to meet the FDA's prescription drug user fee act goal of Aug. 15.
Shares of the company were up 16% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.